Recent Company News

• 07:40 PM ET Oct 21, 2025
  

  FDA accepts sBLA for Astellas Pharma's PADCEV in combination with KEYTRUDA for priority review (¥1622.0000, 0)

• 07:33 PM ET Oct 19, 2025
  

  Astellas Pharma reports first results from open-label extension trial of the Phase 3 GATHER2 study; study results found no new safety signals (¥1606.5000, 0)

• 06:33 AM ET Oct 19, 2025
  

  Pfizer, Astellas announce, publish final OS results from EMBARK study of XTANDI

• 10:37 PM ET Oct 18, 2025
  

  Pfizer, Astellas Pharma's pivotal Phase 3 EV-303 clinical trial for PADCEV shows risk of recurrence and risk of death reduction for certain patients with bladder cancer

• 04:03 PM ET Oct 16, 2025
  

  Taysha Gene Therapies regains full rights to lead TSHA-102 program in clinical evaluation for the treatment of Rett syndrome ($5.08, 0.00)

• 07:40 PM ET Oct 13, 2025
  

  Astellas Pharma's phase 2 GLEAM trial did not meet primary endpoint of OS in patients with metastatic pancreatic cancer (¥1621.0000, 0)

• 08:08 AM ET Oct 09, 2025
  

  Taysha presents new supplemental data analysis from Part A of the REVEAL Phase 1/2 trials for TSHA-102 in Rett Syndrome ($5.06, 0.00)

• 11:10 PM ET Oct 08, 2025
  

  Astellas Pharma downgraded to neutral from buy at Marusan Securities (¥1640.5000, -8.5)

• 04:20 PM ET Oct 02, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 12:50 PM ET Sep 26, 2025
  

  White House says the latest pharmaceutical tariffs do not apply to countries with negotiated trade deals -- wires